The data presented demonstrate that carboplatin dose capping at 110 ml/min results in inferior pCR rates in a cohort of women with early HER2+ breast cancer, receiving potentially curative neoadjuvant therapy. This evidence concerns the gene ERBB2 and breast carcinoma.